NeoGenomics (NEO) has drawn fresh attention after launching RaDaR ST, a circulating tumor DNA assay designed to detect molecular residual disease in blood using patient specific panels and advanced bioinformatics.

Despite the RaDaR ST launch and recent earnings and guidance updates, NeoGenomics' 30 day share price return of 21.23% and year to date share price return of 19.22% both point to fading near term momentum. At the same time, the 5 year total shareholder return of 77.14% highlights a difficult longer term journey for investors.

If this kind of cancer testing news has you thinking about where else growth in medical diagnostics and treatment could emerge, take a look at our screener of 28 healthcare AI stocks as a starting point for other ideas.

With NeoGenomics shares showing a 19.22% decline year to date and a 5-year total shareholder return of 77.14%, along with recent revenue and net income growth, is this weakness creating a buying window, or is the market already pricing in RaDaR ST driven growth?

Most Popular Narrative: 34.2% Undervalued

NeoGenomics' most followed narrative pegs fair value at $14.43 per share compared with the last close at $9.50, framing the current price as a sizeable discount tied to future earnings power and margin improvement.

The commercial launch of PanTracer, a comprehensive liquid biopsy panel for therapy selection, is set to enhance NeoGenomics' competitiveness and capture greater share in the rapidly growing NGS and liquid biopsy segment, supporting revenue acceleration and higher average unit prices (AUP) through 2025 and beyond.

Increased focus on personalized medicine and targeted therapies is driving demand for advanced genomic and MRD testing; NeoGenomics' recent product launches and partnerships position it to benefit from these structural healthcare changes, directly supporting both revenue and higher margin service opportunities.

Analysts behind this widely followed view are effectively sketching a roadmap built on faster test revenue, fatter margins, and a future earnings multiple more often associated with high growth medical names. Curious which assumptions on growth and profitability have to line up to support that fair value and the gap to the current price?

Result: Fair Value of $14.43 (UNDERVALUED)

However, this hinges on pharma demand stabilising and competitors not eroding oncology test share, while litigation or product delays could still upset the earnings path that analysts model.

Another View: Multiples Send A Caution Flag

That 34.2% “undervalued” narrative leans on future earnings power, but today’s pricing tells a different story. NeoGenomics trades on a P/S ratio of 1.7x, compared with a fair ratio of 1.3x, a US Healthcare sector average of 1.3x and a peer average of 1.2x. This points to richer pricing than those benchmarks. If the share price ever drifted closer to that fair ratio, would you see it as an opportunity or a warning that expectations had been too high?

Next Steps

With mixed signals across returns and valuation, are you leaning bullish or cautious on NeoGenomics? If you want to move quickly and rely on more than just headlines, take a closer look at the 1 key reward and 2 important warning signs before you settle on your own view.

Looking for more investment ideas?

If NeoGenomics has sharpened your focus but you are not ready to stop at one stock, use the Simply Wall St screener to hunt for fresh, data driven ideas.

• Target potential mispricings by scanning our list of 45 high quality undervalued stocks that may offer more attractive entry points than headline names.
• Protect your downside by reviewing 76 resilient stocks with low risk scores, where companies score well on stability and risk factors that often matter when markets turn.
• Get ahead of the crowd by checking our screener containing 24 high quality undiscovered gems, where solid fundamentals have not yet translated into widespread attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.